Senolytic Mechanisms
Type Mechanism / biological process
Primary compounds PCC1, Fisetin, Dasatinib, Navitoclax, Quercetin
Overview
Senolytic agents selectively induce apoptosis in senescent cells (SnCs). Senescent cells upregulate Senescent Cell Anti-Apoptotic Pathways (SCAPs) — primarily BCL-2 family overexpression — which shields them from自发 apoptosis. Senolytics disable these shields.
The two primary approaches in the Vitals vault:
- BH3-mimetic / MOMP induction — PCC1 and Fisetin
- BCL-2 family inhibition — Navitoclax, Dasatinib+Quercetin
Why Senescent Cells Are Selectively Vulnerable
Senescent cells overexpress anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1, BCL-W) — their SCAPs. This makes them dependent on these proteins for survival. Normal proliferating cells have lower SCAP expression and wider apoptotic repertoire — making them relatively more resistant.
The vulnerability window: senescent cells are “addicted” to their SCAPs. Disable the specific SCAP and the senescent cell undergoes apoptosis; disable it in a normal cell and the cell has backup anti-apoptotic proteins to compensate.
BH3 Mimetic / MOMP Mechanism
The Core Sequence
BH3 mimetic (PCC1, Fisetin)
→ binds BCL-2/BCL-XL hydrophobic groove
→ displaces pro-apoptotic BAX/BAK
→ mitochondrial outer membrane permeabilization (MOMP)
→ cytochrome c release
→ apoptosome formation
→ caspase-9 activation
→ apoptosis
PCC1 Specifically
- Trimeric procyanidin structure is the key differentiator
- Localizes to senescent mitochondria — healthy mitochondria are spared
- Also upregulates NOXA and PUMA (pro-apoptotic) and downregulates BCL-2/BCL-XL simultaneously
- At low doses (1–20 μM): senomorphic — suppresses SASP without killing cells
- At high doses (50 μM+): full senolytic via MOMP
Fisetin Specifically
- Same BH3-mimetic core as PCC1
- Fisetin also inhibits PI3K/Akt/mTOR — removes survival signals keeping cells senescent
- Disrupts FOXO4-p53 complex — restores p53’s apoptotic function
- logP 3.2 (vs quercetin 1.5) — fisetin penetrates BBB; quercetin does not
Quercetin’s Role
Quercetin is the weak BH3 mimetic — it binds BCL-2/BCL-XL but with lower affinity than fisetin (C5-OH creates steric repulsion in the binding pocket). Dasatinib potentiates quercetin’s effect by multi-kinase inhibition. Quercetin is the reason D+Q works; dasatinib is the amplifier.
Comparison of Senolytic Mechanisms in the Vault
| Compound | Mechanism | Selectivity | Oral | Key Advantage | Key Limitation |
|---|---|---|---|---|---|
| PCC1 | MOMP via Bcl-2/xL displacement + NOXA/PUMA | High | Poor (needs formulation) | First natural senolytic with lifespan extension; no platelet toxicity | Bioavailability |
| Fisetin | BH3 mimetic + PI3K/Akt/mTOR + FOXO4-p53 | High | Moderate (44%) | Best standalone natural senolytic (Mayo); BBB-penetrant | CYP2C9/warfarin; 2024 healthy adult caution |
| Dasatinib + Quercetin | Multi-kinase inhibition (D) + weak BH3 mimetic (Q) | Moderate | Good (both) | Well-studied; works | Dasatinib causes PAH, cytopenias |
| Navitoclax | Direct BCL-2/BCL-XL inhibitor | Moderate | Good | Potent | Thrombocytopenia (platelet apoptosis) |
| FOXO4-DRI | p53 disruption in senescent cells | High | Poor (peptide) | Highly selective | Oral bioavailability zero |
Senolytic vs Senomorphic
| Senolytic | Senomorphic | |
|---|---|---|
| Effect | Kills senescent cells | Suppresses SASP without killing |
| Goal | Reduce senescent cell burden | Reduce inflammation from existing SnCs |
| Dosing | Intermittent (burst) | Continuous |
| Example | PCC1 50 μM+; Fisetin 20 mg/kg × 2 days/month | PCC1 1–20 μM; liposomal Fisetin |
Senolytic dosing is pulsed because senescent cells re-accumulate over weeks to months. Continuous high-dose senolytic may increase off-target effects. Senomorphic dosing (low-dose continuous) is appropriate when the goal is inflammation management rather than clearance.
Stacking: Senolytic + Regenerative
The senolytic window requires a regeneration phase:
- Senolytic clears existing senescent cells
- NAD+ support (NMN/NR) — senescent cells overexpress CD38, draining NAD+; post-clearance NAD+ becomes more available for healthy cells
- GHK-Cu or BPC-157 — rebuild tissue architecture where senescent cells were cleared
- Glutathione — buffers ROS/SASP burst from cell lysis; protects neighboring cells
Wearable / Vitals Relevance
Senescent cell burden is not directly measurable by consumer wearables, but SASP markers are inferable via:
- IL-6, CRP — inflammatory load (blood panel)
- HRV — chronic inflammation depresses parasympathetic tone
- Sleep architecture — SASP cytokines disrupt REM and deep sleep
- Epigenetic age acceleration — TruDiagnostic, GrimAge, etc. — the 2024 fisetin pilot showed 5/10 healthy adults increased biological age, suggesting fisetin was inappropriate for their senescent cell burden level
Links
- PCC1 — MOMP senolytic (trimer)
- Fisetin — BH3-mimetic senolytic (flavonol)
- NMN NAD+ — post-senolytic NAD restoration
- Glutathione — senolytic window ROS buffering
- GHK-Cu — post-clearance tissue remodeling
Source: Nature Metabolism 2021 · Nature Medicine (Robbins/Niedernhofer/Kirkland) · Mayo Clinic AFFIRM-LITE · Gemini Deep Research 2026